About Us
History of Micregen

Following twenty years of scientific research and eighteen months of strategic planning, Micregen was founded in 2015. The proven team of leading business development, biotech industry and stem cell experts are focusing their research on the use of various stem cell types to develop several novel stem cell secretome therapeutics, collectively referred to as Secretomix®. Micregen’s innovative approach and cutting-edge Secretomix® products aim to change how multiple age-related critical and chronic conditions are managed.



Micregen's Secretomix® platform was selected as a finalist for the 2023 UK Pharma Industry Awards, Innovation of the Year.

The Pharma Industry Awards identify and celebrate outstanding individuals and companies within the UK pharma industry who showcase excellence and originality. The Innovation of the Year is reserved for a unique product, process, or technology that yielded significant results and delivered to the highest standard.

This recognition demonstrates the far-reaching potential of Micregen's Secretomix® platform and the significant benefits it could bring to humanity.


Micregen’s first proprietary clinical grade Master and Working Cell banks completed. Both major milestones for the company. The working cell bank is the starting material for production of Micregen’s clinical trials and first commercial products.

Recognising Micregen’s profile as a highly innovative UK company, Micregen's CEO was invited as a guest speaker by UKRI at the London Stock Exchange (LSE) alongside the CEO of UKRI, the CEO of LSE and the UK Government Minister for Science, Research and Innovation to discuss the importance of UK public funding for research and development.


Micregen completed the development of a suite of In-Process-Control, Potency and Release Assays to manufacture clinical grade Secretomix®.


Micregen was selected to join the UK Research and Innovation (UKRI) Scale-Up Program.

The Innovate UK EDGE Scaleup Programme provides one-to-one, bespoke and funded support centred around the specific needs of innovative scaleup companies. Selection for the programme is for the most outstanding scalable businesses that are disrupting their industries, capable of exponential growth and internationalisation.


Pre-clinical research continued throughout 2022 in the UK, USA, and Canada in CRO, university and hospital laboratories.


The UK Medicines Health & Regulatory Authority (MHRA) selected Micregen to join their ‘Innovative Licensing and Access Pathway’ (ILAP).

The entry point to ILAP is through the Innovation Passport, and Micregen was awarded the Innovation Passport for its first product. This pathway aims to accelerate Micregen’s development timeline, facilitating market entry and faster patient access.

Jim Curtis, Commercial Director of Micregen, commented: “This is a significant step for Micregen and will assist us in our desire to advance our cutting-edge treatments.”


Micregen’s new commercial office opened at Alderley Park, Cheshire.


Micregen continues the development of the Secretomix® platform following a successful 2nd scientific advice meeting with the MHRA.


Micregen was listed amongst the UK’s top 200 most valuable high-growth companies in a joint report produced by Singer Capital Markets, a leading investment bank, and Beauhurst, a trusted searchable database of the UK’s high-growth companies.

From the 4.2 million private UK companies, over 34,000 met Beauhurst’s high-growth criteria, nearly 12,000 of which had received qualifying investment over the three-year period covered by the report. Micregen was proud to be placed at 192.


Micregen moved into larger laboratory facilities at Thames Valley Science Park, Reading.

Micregen completed a £5m funding round to meet important milestones through 2023.


Micregen initiated the 2021 funding round led by Pitalia Private Family Office.


Micregen began the cGMP manufacture project of its first therapeutic.


Further financial support from Micregen shareholders with new equity investment as Micregen entered an exciting phase of development.


Micregen shareholders visited Alderley Park for the annual investor meeting.


Micregen appointed pharma business development expert Joanne Kelley as Business Development Director. Jo is a senior biopharmaceutical business development leader with extensive global commercial and general management experience and an outstanding record of strategy development, deal preparation and execution. Her last role at AstraZeneca was VP Business Development - Head of Transactions.

Jo has diverse experience in leading buy and sell life sciences deals, including M&A, licensing, collaboration, and divestments. Her track record includes leading transformational, high-value transactions at AstraZeneca.


Micregen appointed entrepreneur and pharma veteran Jim Curtis as Commercial Director. He has more than 35 years of pharmaceutical industry experience.

Jim has led both Commercial and Research and Development teams across several pharma organisations, including AstraZeneca, Clinigen and Abbott. He has a demonstrable track record of success in Clinical Research, Life Sciences, and Strategic Planning.


Micregen welcomed its stakeholders to Alderley Park for the annual investor meeting.


Micregen attended its first MHRA scientific advisory meeting for its first product under development.


Micregen won a £395k Smart Award under the UK Government’s modern industrial strategy from Innovate UK, part of UK Research and Innovation (UKRI).


Micregen shareholders continue to support the company with further equity investment; new investors include several medical professionals.


Micregen welcomed its stakeholders to Alderley Park for the annual investor meeting.


Micregen shareholders continue to support the company with further equity investment.


Peter Ormerod was appointed as Non-Exec Director. Peter built his family business to an exit with over 400 shops nationwide, which was recognised as the largest Hearing Aid and Audiology provider in the UK.

Peter was also instrumental in the successful sale of the business to the Swiss Sonova Group and the subsequent part sale of the business to Boots the Chemist, including overseeing the rebrand to Boots Hearingcare, which he went on to chair.

Cary Depel was appointed to the Micregen Board. A qualified USA Lawyer & UK Solicitor with an accounting, finance and risk management background, Cary has held positions of Compliance Director and Chief Risk Officer in the UK and USA across several sectors, including biotech and medical device manufacturing. He is a former Fellow and Chairman of the Institute of Risk Management.


First external equity investment welcomed into Micregen.


The scientific team was assembled, including:

Prof. Paolo De Coppi, Professor of Paediatric Surgery at University College London & Great Ormond Street Hospital. Divisional Head at The Institute for Child Health.​

Prof. Ketan Patel, Professor of Regenerative Medicine & Head of Molecular and Cellular Medicine University of Reading, Adjunct Professor at Eppendorf University Clinic, Germany.

Dr Robert Mitchell. Studying under Professor Patel, Rob obtained his PhD at the University of Reading with his thesis exploring the regenerative capabilities of adult stem cell secretomes.


Following twenty years of scientific stem cell research and eighteen months of strategic planning, Micregen was founded by Barry Sharples and Stephen Ray.

Get in touch with us